Pro-survival autophagy and cancer cell resistance to therapy
Resistance to therapy is one of the prime causes for treatment failure in cancer and recurrent
disease. In recent years, autophagy has emerged as an important cell survival mechanism …
disease. In recent years, autophagy has emerged as an important cell survival mechanism …
Promising strategy of mPTP modulation in cancer therapy: an emerging progress and future insight
Cancer has been progressively a major global health concern. With this developing global
concern, cancer determent is one of the most significant public health challenges of this era …
concern, cancer determent is one of the most significant public health challenges of this era …
Chloroquine is a zinc ionophore
J Xue, A Moyer, B Peng, J Wu, BN Hannafon, WQ Ding - PloS one, 2014 - journals.plos.org
Chloroquine is an established antimalarial agent that has been recently tested in clinical
trials for its anticancer activity. The favorable effect of chloroquine appears to be due to its …
trials for its anticancer activity. The favorable effect of chloroquine appears to be due to its …
Imaging the intracellular distribution of tyrosine kinase inhibitors in living cells with quantitative hyperspectral stimulated Raman scattering
ABL1 tyrosine-kinase inhibitors (TKI) are front-line therapy for chronic myelogenous
leukaemia and are among the best-known examples of targeted cancer therapeutics …
leukaemia and are among the best-known examples of targeted cancer therapeutics …
Therapeutic targeting of the mevalonate–geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer
C Guo, R Wan, Y He, SH Lin, J Cao, Y Qiu, T Zhang… - Nature Cancer, 2022 - nature.com
Small cell lung cancer (SCLC) lacks effective treatments to overcome chemoresistance.
Here we established multiple human chemoresistant xenograft models through long-term …
Here we established multiple human chemoresistant xenograft models through long-term …
Cancer cell membrane wrapped nanoparticles for the delivery of a Bcl-2 inhibitor to triple-negative breast cancer
MA Scully, DE Wilkins, MN Dang… - Molecular …, 2023 - ACS Publications
Overexpression of the antiapoptotic protein B-cell lymphoma 2 (Bcl-2) is correlated with poor
survival outcomes in triple-negative breast cancer (TNBC), making Bcl-2 inhibition a …
survival outcomes in triple-negative breast cancer (TNBC), making Bcl-2 inhibition a …
Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers
S Lefort, C Joffre, Y Kieffer, AM Givel, B Bourachot… - Autophagy, 2014 - Taylor & Francis
The triple-negative breast cancer (TN BC) subtype is the most aggressive form of invasive
BC. Despite intensive efforts to improve BC treatments, patients with TN BC continue to …
BC. Despite intensive efforts to improve BC treatments, patients with TN BC continue to …
A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis
S Chen, Y Zhang, L Zhou, Y Leng, H Lin… - Blood, The Journal …, 2014 - ashpublications.org
Bim contributes to resistance to various standard and novel agents. Here we demonstrate
that Bim plays a functional role in bortezomib resistance in multiple myeloma (MM) cells and …
that Bim plays a functional role in bortezomib resistance in multiple myeloma (MM) cells and …
HCC cells with high levels of Bcl-2 are resistant to ABT-737 via activation of the ROS–JNK–autophagy pathway
Z Ni, B Wang, X Dai, W Ding, T Yang, X Li… - Free Radical Biology …, 2014 - Elsevier
Abstract The Bcl-2 inhibitor ABT-737 has shown promising antitumor efficacy in vivo and in
vitro. However, some reports have demonstrated that HCC cells are resistant to ABT-737 …
vitro. However, some reports have demonstrated that HCC cells are resistant to ABT-737 …